What Is the Treatment of Hyperchylomicronaemia? First-Line Dietary and Lifestyle Management
Hyperchylomicronaemia is characterised by markedly elevated triglycerides due to chylomicron accumulation. Without effective management, severely raised triglyceride levels carry a substantial risk of acute pancreatitis. The primary therapeutic objective is to bring triglyceride levels down below the threshold at which significant chylomicronemia occurs.
Clinical Target
Reduce triglyceride levels to below the threshold for significant chylomicronemia (750 to 880 mg/dL) to lower the risk of acute pancreatitis and improve quality of life.
First-Line Approach (Partial Overview)
Management centres on strict dietary fat restriction, alongside specific guidance on alcohol use and avoidance of medications that can raise triglycerides. Ensuring nutritional adequacy in the context of these restrictions is also a key component of the regimen.
The complete structured protocol — including precise dietary targets, supplementation requirements, and full clinical guidance — is available via the link below.
References
DOI: 10.4158/EP-2018-0157
- Current management to reduce triglyceride levels in FCS patients relies on the adoption of a very-low-fat diet consisting of total fat intake <10 to 15% of daily calories (i.e., <20 to 30 g of fat per day).
- In addition to significant limitation of dietary fat, patients need to restrict alcohol intake and avoid certain medications that may elevate triglycerides.
- Patients should also meet National Institutes of Health Institute of Medicine dietary intake recommendations for essential fatty acids (i.e., α-linolenic acid and linoleic acid [1 to 1.5 g/day]), and their diet should be appropriately supplemented with fat-soluble vitamins and minerals.
- Hence, the goal of FCS therapy should be to reduce triglyceride levels in patients to below the threshold for significant chylomicronemia (750 to 880 mg/dL) in order to reduce acute pancreatitis risk and improve the quality of life.
View source ↗